<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146661</url>
  </required_header>
  <id_info>
    <org_study_id>Safestudy5</org_study_id>
    <nct_id>NCT05146661</nct_id>
  </id_info>
  <brief_title>NEURESCUE Device as an Adjunct to Cardiac Arrest</brief_title>
  <acronym>ARISE-EU</acronym>
  <official_title>An In-hospital Feasibility Study of the NEURESCUE Device as an Adjunct to Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>neurescue</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>neurescue</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NEURESCUE device is the first intelligent balloon catheter for aortic occlusion, an&#xD;
      emergency technique that supercharges blood flow to the heart and brain within one minute&#xD;
      from deployment.&#xD;
&#xD;
      The catheter-based device is delivered via the femoral artery, temporarily inflating a soft&#xD;
      balloon in the descending to redirect blood flow towards the upper body.&#xD;
&#xD;
      The objective of the study is to investigate the safety and performance of the NEURESCUE&#xD;
      device as an adjunct to Advanced Life Support (ALS) in adults with cardiac arrest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful balloon inflation within 10 minutes from first vessel puncture</measure>
    <time_frame>Assessed up to 10 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central blood pressure</measure>
    <time_frame>At the initiation of balloon inflation compared to two minutes after finalizing balloon inflation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cardiopulmonary resuscitation (CPR) time at the screening for enrollment</measure>
    <time_frame>From initiation of cardiopulmonary resuscitation (CPR) to screening for enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ALS time at initiation of the investigational procedure</measure>
    <time_frame>From initiation of ALS to initiation of the investigational procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first vessel puncture to successful sheath insertion</measure>
    <time_frame>From first needle stick to successful sheath insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occlusion success</measure>
    <time_frame>Assessed up to 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return of spontaneous circulation (ROSC)</measure>
    <time_frame>Assessed up to 1 hour</time_frame>
    <description>The endpoint is dichotomous (yes/no) for each subject</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Cardiopulmonary Arrest</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The NEURESCUE device will be used as an adjunct to ALS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NEURESCUE device</intervention_name>
    <description>The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤75 years&#xD;
&#xD;
          2. Witnessed cardiac arrest&#xD;
&#xD;
          3. CPR initiated within 7 min of presumed arrest&#xD;
&#xD;
          4. Cardiac arrest not responding to standard ALS&#xD;
&#xD;
          5. Total CPR time ≤ 40 min at the time of screening for enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Traumatic cardiac arrest&#xD;
&#xD;
          2. Known pregnancy&#xD;
&#xD;
          3. Known terminal disease&#xD;
&#xD;
          4. Known Do-Not-Resuscitate (DNR) order&#xD;
&#xD;
          5. Subjects whose femoral arterial access site cannot accommodate an 8 Fr introducer&#xD;
             sheath&#xD;
&#xD;
          6. Subjects currently on mechanical circulatory support&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Preusch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Habib Frost, M.D.</last_name>
    <phone>+4553536760</phone>
    <email>habib.frost@neurescue.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

